سعر اسينابين 5مجم 30 قرص تحت اللسان 2022

Asenapine 5 mg sublingual tablets by Hikma Pharma, an atypical antipsychotic marketed in Egypt; pack of 30 tablets.

• SchizophreniaPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Bipolar I disorder: acute monotherapy of manic or mixed episodesPopulation: Adults and pediatric patients 10-17 yearsDailyMed (U.S. National Library of Medicine)
• Bipolar I disorder: adjunctive treatment to lithium or valproatePopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Most common in adult schizophrenia trials (>=5% and at least twice placebo): akathisia, oral hypoaesthesia and somnolence.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Most common in adult bipolar mania monotherapy (>=5% and at least twice placebo): somnolence, oral hypoaesthesia, dizziness, extrapyramidal symptoms and akathisia; with adjunctive therapy: somnolence and oral hypoaesthesia. Rates were lower at 5 mg than at 10 mg twice daily.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Severe hepatic impairment (Child-Pugh C).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• History of hypersensitivity to asenapine (reactions have included anaphylaxis, angioedema, hypotension, tachycardia, swollen tongue, dyspnoea, wheezing and rash).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity to the active substance or to any of the excipients.International label, equivalent formulation · European Medicines Agency (EPAR product information)

• Boxed warning: elderly patients with dementia-related psychosis treated with antipsychotics have an increased risk of death; asenapine is not approved for dementia-related psychosis.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Cerebrovascular adverse events (stroke, transient ischaemic attack) were increased in elderly patients with dementia-related psychosis.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Neuroleptic malignant syndrome (discontinue immediately and monitor) and tardive dyskinesia (discontinue if clinically appropriate) may occur.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Antihypertensive drugsAlpha1-adrenergic antagonism may enhance hypotensive effects; monitor blood pressure and adjust the antihypertensive dose.DailyMed (U.S. National Library of Medicine)
• Strong CYP1A2 inhibitors (e.g. fluvoxamine)Asenapine is metabolised by CYP1A2; full therapeutic fluvoxamine doses are expected to increase asenapine exposure; asenapine dose reduction may be necessary.DailyMed (U.S. National Library of Medicine)
• Paroxetine and other CYP2D6 substrates/inhibitorsAsenapine doubled paroxetine exposure; reduce the paroxetine dose by half when combined.DailyMed (U.S. National Library of Medicine)

• No human data inform the drug-associated risk; neonates exposed to antipsychotics in the third trimester are at risk of extrapyramidal and/or withdrawal symptoms; advise pregnant women of the potential fetal risk. A pregnancy exposure registry exists.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• No adequate data in pregnant women; should not be used during pregnancy unless the woman's clinical condition requires asenapine and the benefit outweighs the potential fetal risk.International label, equivalent formulation · European Medicines Agency (EPAR product information)
• No human lactation data; asenapine is excreted in rat milk; weigh breastfeeding benefits against the mother's need for treatment and potential infant effects.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Asenapine: Mechanism unknown; efficacy in schizophrenia may be mediated by combined antagonism at dopamine D2 and serotonin 5-HT2A receptors; high affinity for multiple serotonin, dopamine, alpha-adrenergic and H1 receptors, no appreciable muscarinic affinity (US SAPHRIS label).